Assembly Biosciences

68 articles with Assembly Biosciences

• 

  BioSpace Movers & Shakers, Oct. 23

  10/23/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Assembly Biosciences Appoints Gina Consylman to Board of Directors

  10/20/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact AwardDr. McHutchison Recognized for Critical Achievements in Developing Curative Treatments for Chronic Hepatitis

  10/15/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison AO, MD – the company’s CEO and president– was named the recipient of the Advance 2020 Global Impact award. The Advance awards recognize the work of remarkable global Australians making an extraordinary

• Assembly Biosciences Announces October Conference Participation

  10/5/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV. ICE-HBV Serum Biomarkers Virtual Workshop 2020 Panel: What are the virological and immunological gaps that need to be addressed? What biomarkers are most needed to

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 31,520 shares of the Company’s common stock with an exercise price of $17.29 per share, the closing price of Assembly’s common stock on October 1, 2020.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 04, 2020

  9/4/2020

  Assembly Biosciences, Inc. announced grants of stock options to five new employees to purchase an aggregate of 86,000 shares of the Company’s common stock with an exercise price of $20.14 per share, the closing price of Assembly’s common stock on September 1, 2020.

• Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020

  8/28/2020

  Assembly Biosciences, Inc. announced that clinical data for its lead HBV core inhibitor vebicorvir, its second-generation core inhibitor ABI-H2158, as well as its highly sensitive HBV assays were highlighted during The Digital International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver.

• Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection

  8/27/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus (HBV) core inhibitor candidate ABI-H0731 in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 07, 2020

  8/7/2020

  Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 13,000 shares of the Company’s common stock with an exercise price of $23.08 per share, the closing price of Assembly’s common stock on August 3, 2020.

• Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

  8/5/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, reported financial results and recent highlights for the second quarter ended June 30, 2020.

• Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

  7/20/2020

  BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China

• Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection

  7/9/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2020

  7/2/2020

  Assembly Biosciences, Inc. announced grants of stock options to ten new employees to purchase an aggregate of 112,600 shares of the Company’s common stock with an exercise price of $23.30 per share, the closing price of Assembly’s common stock on July 1, 2020.

• Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection

  6/25/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation of a Phase 2 trial of its potent, second-generation core inhibitor, ABI-H2158 (2158). The international multi-center, randomized, placebo-controlled trial will evaluate 2158 with entecavir versus placebo with

• Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II

  6/22/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that preclinical data from its immuno-oncology microbiome program are currently being featured in an e-poster at the American Association for Cancer Research Virtual Annual Meeting II , June 22-24, 2020. The poster, Dis

• Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs

  6/18/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the Company will regain worldwide rights to all microbiome gastrointestinal programs licensed under its collaboration agreement with AbbVie

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.

• Assembly Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  6/1/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced grants of inducement awards to both its Chief Scientific Officer, Virology, William Delaney, Ph.D., and eight new employees on May 27, 2020 and June 1, 2020, respectively.

• Assembly Biosciences Announces Management Transition

  5/27/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced the appointment of William Delaney, PhD as Chief Scientific Officer, Virology, replacing Richard Colonno, PhD, who will retire and transition from this role on June 1, 2020.